Recursion Launches V
Recursion Launches Valence Labs at ICML with a Commitment to Open Science Including $1 Million in Academic Scholarships
July 26, 2023 18:58 ET | Recursion Pharmaceuticals
SALT LAKE CITY, July 26, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today launched Valence Labs at...
MustangBioLogo.jpg
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
June 15, 2023 16:01 ET | Mustang Bio, Inc.
10 out of 20 patients remain in complete remission for more than a year 95% overall response rate (ORR) and 80% complete response (CR) rate across all patients; 100% ORR and 91% CR with higher dose...
MustangBioLogo.jpg
Mustang Bio Announces Upcoming Presentations of Clinical Data from Phase 1/2 Trial of MB-106, a CD20-Targeted Autologous CAR T Cell Therapy
May 11, 2023 16:03 ET | Mustang Bio, Inc.
Data from Waldenstrom macroglobulinemia cohort selected for poster presentation at EHA2023 Outpatient treatment of follicular lymphoma selected for oral presentation at ICML WORCESTER, Mass., May ...
INNATEvertnoir.png
Innate Pharma presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides
June 22, 2021 07:00 ET | INNATE PHARMA
Marseille, June 22, 2021 (GLOBE NEWSWIRE) -- First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2 Data...
INNATEvertnoir.png
Innate Pharma présente des données préliminaires de l'essai TELLOMAK montrant une réponse clinique avec lacutamab dans le mycosis fungoides
June 22, 2021 07:00 ET | INNATE PHARMA
Marseille, 22 juin 2021 (GLOBE NEWSWIRE) -- Les premières données cliniques de TELLOMAK établissent la sécurité de lacutamab, des réponses cliniques ainsi qu’une amélioration au niveau de la peau...
BEI_ONC_4C_FlatLogo_Horizontal.jpg
BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)
June 12, 2019 04:00 ET | BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...